Companies · Biotechnology

Recros Medica, Inc.

SAN DIEGO · Biotechnology

Diligence memoA one-page analyst read on Recros Medica, Inc. — recommendation, valuation, rhythm, risks.
$9.9M
Total raised · real
3
Rounds
4.3×
Latest step-up
Top 45%
Sector rank · raised
Series A
Latest stage · inferred · Fri Dec 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Recros Medica, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.71× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
  • Within the normal band (71% of peer median) for its niche.
Dormant
  • Last raise 7.5 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Recros Medica, Inc. is one of 4293 Biotechnology companies tracked from SAN DIEGO. By capital raised it ranks mid-pack (ahead of 56% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
47
Investors (latest)
2014
Year incorporated
2018-12-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2014-08-27 Raised $1.4M (real) Modeled valuation $61M (est)$1.4M$61MSeed2014Pre-Seed · 2014-08-27 Raised $250K (real) Modeled valuation $14M (est)$250K$14MPre-Seed2014Series A · 2016-06-09 Raised $4.4M (real) Modeled valuation $160M (est)$4.4M$160MSeries A2016Pre-Seed · 2016-06-09 Raised $950K (real) Modeled valuation $52M (est)$950K$52MPre-Seed2016Series A · 2018-12-21 Raised $4.1M (real) Modeled valuation $149M (est)$4.1M$149MSeries A2018+$250K+$4.4M+$950K+$4.1MCumulative $11M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.4M · 2014
Bridge · Seed-stage$250K · 2014smaller follow-on
Series A$4.4M · 2016
Bridge · Series A-stage$950K · 2016smaller follow-on
Series A extension$4.1M · 2018

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$149.0M
Base estimate est.
$4.5M
Conservative case
$810.2M
Upside case
$18.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $60.6M · 2014-08-272014Pre-Seed · modeled $13.8M · 2014-08-27Series A · modeled $159.5M · 2016-06-09Pre-Seed · modeled $52.4M · 2016-06-09Series A · modeled $149.0M · 2018-12-212018
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
7.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$2.3M/yr
Capital velocity
11.8 yr
On record since
2014
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.4× above median
This company$9.9M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.8× of median
This company$4.1M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.3× above median
This company$149.0M
Sector median$64.2M

Raised more than 56% of sector peers (real $). Modeled value above 66% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #117 of 157.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Bio-Dent, LTD. LLC · Series A Raised $15.0M · modeled $542.3M (est)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Cynvec LLC · Series A Raised $17.4M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)Recros Medica, Inc. (this company) Raised $9.9M · modeled $149.0M (est)Recros Medica, Inc.
CompanyStageRaised · realValue · estvs peer med.
Bio-Dent, LTD. LLCSeries A$15.0M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Cynvec LLCSeries A$17.4M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
Recros Medica, Inc. this companySeries A$9.9M$149.0M0.71×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.4M2014-08-27$6.8M$60.6M85%
Pre-Seed$250K2014-08-27$1.4M$13.8M85%
Series A$4.4M2016-06-09$20.1M$159.5M90%
Pre-Seed$950K2016-06-09$5.3M$52.4M85%
Series A$4.1M2018-12-21$18.7M$149.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.4M2014-08-27
    • First recorded raise — entered as Seed.
    • 5 investors on this round.
  2. Pre-Seed$250K2014-08-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.5× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  3. Series A$4.4M2016-06-09
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 17.7× larger than the prior — scaling up.
    • 44 investors on this round.
  4. Pre-Seed$950K2016-06-09
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.6× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  5. Series A$4.1M2018-12-21
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 4.3× larger than the prior — scaling up.
    • 47 investors on this round.
Intelligence
2020 ~Q1
Modeled next raise · ~13mo cadence
$12.4M
Modeled next size est.range $8.0M$19.8M
4.3×
Last step-up
$2.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David F Hale15 other2014-08
Kathleen D. Scott4 other2014-08
Thomas A. Albright1 other2018-12
Cathy F. McCarthy2014-08
Cathy L. McCarthy2016-06
Christoph J. Westphal2018-12
Edward F. Knowlton, M.D.2014-08
Mark J. Kerslake2018-12
Milind K. Ambe, M.D.2014-08
Registry & provenance

Recros Medica, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1619033
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Mdrejuvena, Inc.BiotechnologySeed$6.2M$107.5Mnetwork2 shared operators · same sector
Ridge Diagnostics, Inc.BiotechnologySeries A$7.4M$9.0Mnetwork1 shared operator · same sector · same stage
Dermata Therapeutics, LLCBiotechnologySeries A$16.2M$106.3Mnetwork1 shared operator · same sector · same stage
Neurana Pharmaceuticals, Inc.BiotechnologySeries C$45.7M$1.7Bnetwork2 shared operators · same sector
Andrew Technologies LLCBiotechnologySeries A$21.8M$26.7Mnetwork1 shared operator · same sector · same stage
Biocept IncBiotechnologySeries A$35.7M$366.4Mnetwork1 shared operator · same sector · same stage
Adigica Health, Inc.HealthtechSeries A$21.8M$18.2Mnetwork2 shared operators · same stage
Mill Creek Life Sciences, LLCBiotechnologySeries A$9.9M$180.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
ReCor Medical, Inc.BiotechnologySeries B$873.2M92%
Recombinetics, IncBiotechnologySeries B$1.3B90%
Recibio, Inc.BiotechnologySeed$6.5M90%
Santiste Medical Inc.BiotechnologyPre-Seed$10.3M88%
Regenerative Medical Solutions, Inc.BiotechnologySeries A$39.6M88%
Biorez, Inc.BiotechnologySeries A$89.1M87%
Reprogram Biosciences, Inc.BiotechnologyPre-Seed$2.7M87%
Rejoni, Inc.BiotechnologySeries B$364.1M87%
Frequently asked
How much funding has Recros Medica, Inc. raised?
Recros Medica, Inc. has raised approximately $9.9M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Recros Medica, Inc.'s estimated valuation?
Provath's modeled valuation for Recros Medica, Inc. is approximately $149.0M (modeled range $4.5M–$810.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Recros Medica, Inc. at?
Recros Medica, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Dec 21.
What does Recros Medica, Inc. do and where is it based?
Recros Medica, Inc. operates in the Biotechnology sector, based in SAN DIEGO.
Explore related

See where Recros Medica, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Recros Medica, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.